Monitoring Force Group
A Valued Partner in Drug Development

Biopharma companies often face tremendous complications and unforeseen risks in developing drugs in spite of careful planning. With clinical trial outsourcing a norm today, clients face multiple challenges with CROs in the form of overextended budgets and unrealistic timelines at the end of a project. Sponsors need support from experts who can guide them through the complex stages of drug development.

Aware of these predicaments in the biopharma industry, Dr. Amin Kadi strived to tackle these woes by founding Monitoring Force Group. As a global CRO, Monitoring Force challenges the misconception that “a CRO has to be large to be good” by taking a personalized approach to complete projects on time and on budget.

Monitoring Force proposes end-to-end support, from early drug development to regulatory approval. It offers specific development concept and management services that take the heavy lifting off the clients’ shoulders. Nimble and flexible, the CRO seeks to find the best solutions to clients’ unique needs by customizing its services. “Our team has specialized knowledge of drug development, industry regulations, protocols, and study designs required to evaluate the health product under development in the patient population,” says Dr. Kadi. With extensive expertise in clinical trials, the CRO has an expert project management approach that places a continuous emphasis on accountability, flexibility, and strong communication, ensuring smooth project completion. “We take the ownership of outcomes and deliverables throughout the project lifecycle,” adds Dr. Kadi.

We take the ownership of outcomes and deliverables throughout the project lifecycle

In addition, Monitoring Force has made significant efforts to differentiate itself from its competitors by setting up early an Early Access Program (EAP). From strategy development to submission of request files, the CRO helps the client setup and reap the benefits of the program.

What’s more, Monitoring Force provides its clients with a team specialized in medical writing. The team meets the requirements of international publications and has developed a patient-oriented approach whose needs and expectations must always be taken into account in pre- and post-MA (Marketing Authorisation) development.

Dr. Kadi talks about a recent study that Monitoring Force executed with a device that allowed dialysis at home. Aligning with the sponsor’s budgets and deadlines, the CRO chalked out a precise clinical development plan to obtain the required certification. Furthermore, it conducted the feasibility and pivotal studies needed for the program and helped the client market the product sooner. To accelerate profit, Monitoring Force conducted a real-life study that allowed the client to stand out from its competitors.

Founded by two neurologists in Germany, Monitoring Force Group started operating as a CRO specialized in studies related to Parkinson’s disease. In 2003, Dr. Kadi took the reins of the company to form a global CRO and health products services organization. With an experienced team of physicians and specialists in methodology and statistics, Kadi has conquered new territories with branch offices in Europe, North Africa, and the Middle East (MENA).

Monitoring Force holds a proven track record from the regulatory and compliance perspectives. This has helped the company win the confidence and trust of its global clientele. Monitoring Force looks forward to taking its value to new locations across Europe and MENA. “Customer- and patient-centricity are our core values, and we strive to be flexible and attentive to our clients’ needs,” concludes Dr. Kadi.